Teva Pharma (TEVA) and Active Biotech (ACTI) Said Data Confirms Neuroprotective and Anti-Inflammatory Properties of MS Treatment
More News related to ACTI
- Exploratory data presented for Active Biotech's ANYARA project
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- TEVA ACQUIRES MARKETING RIGHTS FOR ORAL LAQUINIMOD IN THE NORDIC AND BALTIC REGIONS
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
More News related to TEVA
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
- Teva Pharma (TEVA) Settles with Ven-A-Care; To Record Charge of $315M for Q409
- Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ: ACTI) today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.
Results from several preclinical studies suggest that laquinimod elicits a protective therapeutic effect by reducing demyelination and inducing axonal protection.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
